Argos Therapeutics, an immune-oncology company focused on the development and commercialization of individualized immunotherapies headquartered in Durham, has signed a lease on a 40,000-square-foot manufacturing space at the Center for Technology & Innovation on the Centennial Campus of North Carolina State University.

Argos plans to use this space for a submission of a biologics license application to the U.S. Food and Drug Administration and to support initial commercialization of rocapuldencel-T, which is being evaluated for the treatment of metastatic renal cell carcinoma. The company will be able to support domestic and international launches for rocapuldencel-T.

“Out two-stage manufacturing strategy positions us to employ an established and proved effective manual manufacturing process at CTI with the capacity to support approximately 1,800 patients per year at launch, with expansion capacity of 2,400 patients per year,” said Jeff Abbey, CEO of Argos.

Its shares closed at $4.95 on Monday, down 15 cents from the morning’s opening stock price.

“In our role of facilitating economic development, we applaud the commitment Argos is making to extend its research partnerships,” said Dr. Alan Rebar, vice chancellor of research, innovation and technology of NC State. “We are excited that Argos has chosen CTI as it seeks to develop and commercialize cutting-edge immunotherapies for people with serious illnesses.”

Argos began at Rockefeller University, when company co-founder and Nobel Prize winner, Dr. Ralph Stienman, discovered the role of dendritic cells in the immune system and developed a method to generate these cells.

The filing can be found here.